{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:50:44Z","timestamp":1793260244064,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003172","name":"Henan University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.neuropharm.2024.109952","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T12:38:02Z","timestamp":1714048682000},"page":"109952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?"],"prefix":"10.1016","volume":"253","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-3260","authenticated-orcid":false,"given":"Christian","family":"H\u00f6lscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.109952_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2024.109952_bib4","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The Impact of type 2 diabetes in Parkinson's disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2024.109952_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JPD-181329","article-title":"What effects might exenatide have on non-motor symptoms in Parkinson's disease: a post hoc analysis","volume":"8","author":"Athauda","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109952_bib7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2024.109952_bib8","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2024.109952_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 Months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109952_bib10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2024.109952_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12760","article-title":"Impaired brain insulin signalling in Parkinson's disease","volume":"48","author":"Bassil","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JPD-191900","article-title":"The association between type 2 diabetes mellitus and Parkinson's disease","volume":"10","author":"Cheong","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109952_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1054\/npep.1999.0757","article-title":"Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain","volume":"33","author":"Chowen","year":"1999","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2024.109952_bib14","first-page":"503","article-title":"Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus","volume":"12","author":"Christensen","year":"2009","journal-title":"Idrugs"},{"key":"10.1016\/j.neuropharm.2024.109952_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/156720509787602870","article-title":"Development of a non invasive NGF-based therapy for Alzheimer's disease","volume":"6","author":"Covaceuszach","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2024.109952_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0166-2236(02)02181-1","article-title":"The placebo effect in Parkinson's disease","volume":"25","author":"de la Fuente-Fernandez","year":"2002","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109952_bib17","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.neuropharm.2024.109952_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.55.1.7","article-title":"Pharmacological agents that directly modulate insulin secretion","volume":"55","author":"Doyle","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2024.109952_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2024.109952_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00401-023-02557-1","article-title":"Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges","volume":"145","author":"Dutta","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib21","article-title":"Evaluation of liraglutide in the treatment of Alzheimer's disease","volume":"17","author":"Edison","year":"2022","journal-title":"Alzheimer & Dementia"},{"key":"10.1016\/j.neuropharm.2024.109952_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/alz.080538","article-title":"Mri changes following treatment of GLP-1 analogue, liraglutide in ALZHEIMER\u2019S disease: elad trial","volume":"19","author":"Edison","year":"2023","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2024.109952_bib23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s13063-020-04608-4","article-title":"Correction to: evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","volume":"21","author":"Femminella","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.neuropharm.2024.109952_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109952_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108277","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"239","author":"Ferrari","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2024.109952_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuropharm.2024.109952_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/mds.27941","article-title":"Diabetes, BMI, and Parkinson's","volume":"35","author":"Foltynie","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2024.109952_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.neuropharm.2024.109952_bib29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib30","author":"Hogg"},{"key":"10.1016\/j.neuropharm.2024.109952_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases","volume":"42","author":"Holscher","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2024.109952_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","article-title":"Brain insulin resistance: role in neurodegenerative disease and potential for targeting","volume":"29","author":"H\u00f6lscher","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.neuropharm.2024.109952_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2022.955258","article-title":"Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases","volume":"14","author":"H\u00f6lscher","year":"2022","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109952_bib34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bph.15508","article-title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","volume":"179","author":"H\u00f6lscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","article-title":"Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes","volume":"55","author":"Iwai","year":"2006","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2024.109952_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tins.2018.09.007","article-title":"Triggers, facilitators, and aggravators: redefining Parkinson's disease pathogenesis","volume":"42","author":"Johnson","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109952_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib39","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2024.109952_bib40","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2024.109952_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109952_bib42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.109952_bib44","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/mds.22173","article-title":"Cut-off score of the Mattis dementia rating scale for screening dementia in Parkinson's disease","volume":"23","author":"Llebaria","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2024.109952_bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.neuropharm.2024.109952_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav"},{"key":"10.1016\/j.neuropharm.2024.109952_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of alzheimer's disease","volume":"35","author":"Maskery","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.neuropharm.2024.109952_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1533317511412046","article-title":"Mattis dementia rating scale 2: screening for MCI and dementia","volume":"26","author":"Matteau","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.neuropharm.2024.109952_bib49","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109952_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib51","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2024.109952_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s43556-021-00040-5","article-title":"Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases","volume":"2","author":"Meldolesi","year":"2021","journal-title":"Mol Biomed"},{"key":"10.1016\/j.neuropharm.2024.109952_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","article-title":"Insulin resistance impairs nigrostriatal dopamine function","volume":"231","author":"Morris","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2024.109952_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.neuropharm.2024.109952_bib56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-180578","article-title":"Extracellular vesicle biomarkers track cognitive changes following intranasal insulin in alzheimer's disease","volume":"69","author":"Mustapic","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2024.109952_bib57","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrd3366","article-title":"Potential therapeutic uses of BDNF in neurological and psychiatric disorders","volume":"10","author":"Nagahara","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2024.109952_bib58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0301-0082(02)00127-2","article-title":"An inflammatory review of Parkinson's disease","volume":"68","author":"Orr","year":"2002","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.neuropharm.2024.109952_bib59","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2024.109952_bib60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","article-title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","volume":"700","author":"Parthsarathy","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1389450043345245","article-title":"A new Alzheimer's disease interventive strategy: GLP-1","volume":"5","author":"Perry","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2024.109952_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.109952_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28496-6","article-title":"Integrated brain atlas for unbiased mapping of nervous system effects following liraglutide treatment","volume":"8","author":"Salinas","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2024.109952_bib65","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to Methylglyoxal stress","volume":"128","author":"Sharma","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.109952_bib66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","article-title":"A novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","volume":"327","author":"Shi","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.109952_bib67","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejphar.2015.09.024","article-title":"Exenatide reduces TNF-alpha expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats","volume":"765","author":"Solmaz","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/nmt.13.73","article-title":"Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs","volume":"4","author":"Talbot","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.neuropharm.2024.109952_bib69","series-title":"INSULIN RESISTANCE IN the CEREBRAL CORTEX of COGNITIVELY IMPAIRED PARKINSON\u2019S DISEASE (PD) CASES IS REDUCED by EXENATIDE and the DUAL INCRETIN RECEPTOR AGONIST DA4-JC. AD\/PD Conference, Gothenburg, Sweden","author":"Talbot","year":"2023"},{"key":"10.1016\/j.neuropharm.2024.109952_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2024.109952_bib71","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/1871527320666210526160926","article-title":"Immunotherapies for Parkinson's disease: progression of clinical development","volume":"20","author":"Teng","year":"2021","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.neuropharm.2024.109952_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112485","article-title":"Extracellular vesicles in alzheimer's and Parkinson's disease: small entities with large consequences","volume":"9","author":"Vandendriessche","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.109952_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109716","article-title":"Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R\/SIRT1\/GLUT4 pathway","volume":"240","author":"Wang","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.109952_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0053-14.2015","article-title":"Growth hormone secretagogue receptor dimers: a new pharmacological target","volume":"2","author":"Wellman","year":"2015","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2024.109952_bib75","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awz023","article-title":"Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease","volume":"142","author":"Whone","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2024.109952_bib76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","article-title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease","volume":"26","author":"Yang","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2024.109952_bib77","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/alz.12474","article-title":"Brain energy failure in dementia syndromes: opportunities and challenges for glucagon-like peptide-1 receptor agonists","volume":"18","author":"Yassine","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuropharm.2024.109952_bib78","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.neuropharm.2024.109952_bib79","article-title":"DA5-CH and semaglutide protect against neurodegeneration and reduce alpha-synuclein levels in the 6-OHDA Parkinson's disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.neuropharm.2024.109952_bib80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces alpha-synuclein levels in the chronic MPTP mouse model of Parkinson's disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2024.109952_bib81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JPD-191768","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson's disease","volume":"10","author":"Zhang","year":"2020","journal-title":"J Parkinson Dis"},{"key":"10.1016\/j.neuropharm.2024.109952_bib82","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4103\/1673-5374.303045","article-title":"Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model","volume":"16","author":"Zhang","year":"2021","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neuropharm.2024.109952_bib83","article-title":"GIP has neuroprotective effects in Alzheimer and Parkinson's disease models","author":"Zhang","year":"2019","journal-title":"Peptides"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:35:06Z","timestamp":1715934906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":82,"alternative-id":["S0028390824001217"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109952","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.109952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109952"}}